GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class

GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression ...
Nasdaq

Genscript Biotech Strikes Lucrative Licensing Deal

Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s subsidiary, Probio Nanjing, has entered into a significant license agreement with LaNova Medicines, granting exclusive rights to ...
FiercePharma

Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual ...
Morningstar

GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

GenScript Biotech Corporation: GenScript Launches TurboCHO Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class

New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 12, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of ...